Intramyocardial cell-based therapy with Lomecel-B during bidirectional cavopulmonary anastomosis for hypoplastic left heart syndrome: the ELPIS phase I trial
Open Access
- 11 January 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 3 (2) , oead002
Abstract
Hypoplastic left heart syndrome (HLHS) survival relies on surgical reconstruction for the right ventricle (RV) to provide systemic circulation. This substantially increases the RV load, wall stress, maladaptive remodeling, and dysfunction, which in turn increases the risk of death or transplantation. We conducted a phase 1 open-label multicenter trial to assess the safety and feasibility of Lomecel-B as an adjunct to second stage HLHS surgical palliation. Lomecel-B, an investigational cell therapy consisting of allogeneic medicinal signaling cells (MSCs), was delivered via intramyocardial injections. The primary endpoint was safety, and measures of RV function for potential efficacy were obtained. Ten patients were treated. None experienced major adverse cardiac events (MACE). All were alive and transplant-free at 1-year post-treatment, and experienced growth comparable to healthy historical data. Cardiac magnetic resonance imaging (CMR) suggested improved tricuspid regurgitant fraction (TR RF) via qualitative rater assessment, and via significant quantitative improvements from baseline at 6 and 12 months post-treatment (p < 0.05). Global longitudinal strain (GLS) and RV ejection fraction (EF) showed no declines. To understand potential mechanisms of action, circulating exosomes from intramyocardially transplanted MSCs were examined. Computational modeling identified 54 MSC-specific exosome RNAs corresponding to changes in TR RF, including miR-215-3p, miR-374b-3p, and RNAs related to cell metabolism and MAPK signaling. Intramyocardially-delivered Lomecel-B appears safe in HLHS patients and may favorably affect RV performance. Circulating exosomes of transplanted MSC-specific provide novel insight into bioactivity. Conduct of a controlled phase trial is warranted and is underway.Keywords
Funding Information
- Maryland Stem Cell Research Fund (#2017-MSCRFCL-3955)
- Children’s Heart Foundation
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL118491, R01 HL139060-01A1, R42HL131226-01)
- Moseley Foundation
- NIH
- National Heart, Lung, and Blood Institute (R01 HL107110, 1R01HL134558-01, 4R01HL084275-10, 5R01HL116899-04, HHSN268201600012I)
- NIH
- National Cancer Institute (5R01CA136387-07)
- Soffer Family Foundation
- Marcus Foundation
- Starr Foundation
- National Institutes of Health
- National Institute on Aging, the MSCRF, and Alzheimer’s Association
- NIH
- National Heart, Lung, and Blood Institute (R01HL145644)
This publication has 42 references indexed in Scilit:
- Early survival after heart transplant in young infants is lowest after failed single-ventricle palliation: A multi-institutional studyThe Journal of Heart and Lung Transplantation, 2012
- Usefulness of B-Type Natriuretic Peptide and N-Terminal Pro-B-Type Natriuretic Peptide as Biomarkers for Heart Failure in Young Children With Single Ventricle Congenital Heart DiseaseThe American Journal of Cardiology, 2012
- Hypoplastic Left Heart SyndromeJACC, 2012
- Intramyocardial Stem Cell Injection in Patients With Ischemic CardiomyopathyCirculation Research, 2011
- A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Intravenous Adult Human Mesenchymal Stem Cells (Prochymal) After Acute Myocardial InfarctionJACC, 2009
- Usefulness of Various Plasma Biomarkers for Diagnosis of Heart Failure in Children With Single Ventricle PhysiologyThe American Journal of Cardiology, 2009
- Prevalence of Congenital Heart Defects in Metropolitan Atlanta, 1998-2005The Journal of Pediatrics, 2008
- Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cellsBlood, 2005
- HLA expression and immunologic propertiesof differentiated and undifferentiated mesenchymal stem cellsExperimental Hematology, 2003
- Management of hypoplastic left heart syndrome in a Consortium of University HospitalsThe American Journal of Cardiology, 1995